Nechemia Peres - Teva Pharmaceutical Independent Director
| TEVJF Stock | USD 11.75 0.23 1.92% |
Director
Mr. Nechemia Jacob Peres is Independent Director of the Company. Mr. Peres joined the Board of Directors in July 2017. Mr. Peres serves as the managing general partner and cofounder of Pitango VC, Israels largest VC group that invests across technology sectors from IT to healthcare, with over 220 portfolio companies, since its inception in 1996. Mr. Peres serves on the board of directors of numerous Pitango portfolio companies. Mr. Peres is also the founder of Mofet Israel Technology Fund, one of Israels first VC funds, since its inception in 1992 since 2017.
| Age | 58 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 972 3 914 8213 |
| Web | https://www.tevapharm.com |
Teva Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Thomas Haughey | ANI Pharmaceuticals | 54 | |
| John Paulson | Bausch Health Companies | 64 | |
| Yvonne Greenstreet | Pacira Pharmaceuticals | 55 | |
| Robert Power | Bausch Health Companies | 63 | |
| Michael Barber | Catalent | 60 | |
| Madhavan Balachandran | Catalent | 69 | |
| Mark Kronenfeld | Pacira Pharmaceuticals | 63 | |
| Robert Hale | Bausch Health Companies | 33 | |
| Rosemary Crane | Catalent | 60 | |
| Allan Oberman | Dr Reddys Laboratories | 62 | |
| Bharat Doshi | Dr Reddys Laboratories | 71 | |
| Paul Mitchell | Alkermes Plc | 64 | |
| Omkar Goswami | Dr Reddys Laboratories | 61 | |
| J Moreau | Dr Reddys Laboratories | 64 | |
| Maryscott Greenwood | Tilray Inc | 51 | |
| James Quella | Catalent | 68 | |
| Nancy Snyderman | Alkermes Plc | 66 | |
| Bruce Carter | Dr Reddys Laboratories | 77 | |
| Bruce McEvoy | Catalent | 37 | |
| Lucier Gregory | Catalent | 50 | |
| Shikha Sharma | Dr Reddys Laboratories | 62 | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 |
Teva Pharmaceutical Leadership Team
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nechemia Peres, Independent Director | ||
| Moshe Many, Independent Director | ||
| Roger Abravanel, Independent Director | ||
| Richard Daniell, Executive Vice President - European Commercial | ||
| Eyal Desheh, CFO and Group Executive VP | ||
| Mark Sabag, Group Executive Vice President Human Resources | ||
| Richard Lerner, Independent Director | ||
| Galia Maor, Independent Director | ||
| Gianfranco Nazzi, Executive Vice President - Growth Markets Commercial | ||
| Kare Schultz, CEO Pres | ||
| Carlo Notaristefani, CEO of Global Operations and President of Global Operations | ||
| Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication | ||
| Amir Weiss, VP Officer | ||
| Brendan OGrady, Executive Vice President - North America Commercial | ||
| JeanMichel Halfon, Statutory - independent director | ||
| Michael Hayden, President - Global Research and Development, Chief Scientific Officer | ||
| Gabrielle Sulzberger, Statutory Independent Director | ||
| Eli Shani, Ex Portfolio | ||
| Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations | ||
| Eric Drape, Ex Operations | ||
| Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee | ||
| Yitzhak Peterburg, Director | ||
| Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
| Eliyahu Kalif, Ex CFO | ||
| Kathleen Veit, Global VP | ||
| Joseph Nitzani, Independent Director | ||
| Timothy Wright, Head - Business Development, Strategy and Innovation | ||
| Perry Nisen, Independent Director | ||
| Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director | ||
| Sigurdur Olafsson, CEO of Global Generic Medicines Group and President of Global Generic Medicines Group | ||
| David Stark, Chief Legal Officer | ||
| Murray Goldberg, Independent Director | ||
| Dan Propper, Independent Director | ||
| Ory Slonim, Independent Director | ||
| Michael McClellan, CFO, Executive Vice President | ||
| Kevin Mannix, Head of Global Investor Relations and VP | ||
| Amir Elstein, Vice Chairman of the Board | ||
| Kaare Schultz, President CEO | ||
| Dan Suesskind, Director | ||
| Arie Belldegrun, Independent Director | ||
| Richard Egosi, Chief Legal Officer and Group Executive VP | ||
| Sol Barer, Director | ||
| Jean Halfon, Statutory - independent director | ||
| Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio | ||
| Robert Koremans, President CEO-Global Specialty Medicines | ||
| Gerald Lieberman, Director | ||
| Roberto Mignone, Independent Director | ||
| Rosemary Crane, Director |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 28.75 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 5.30 % | |||
| Price To Earning | 14.56 X | |||
| Price To Book | 1.10 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Teva Pink Sheet analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |